DC
VKTX icon

Diametric Capital’s Viking Therapeutics VKTX Stock Holding History

Diametric Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,896
Closed -$2.08M – 692
2026
Q1 		$2.08M Buy
+63,896
New +$2.05M 0.54% 33
2024
Q4 		– Sell
-4,124
Closed -$261K – 455
2024
Q3 		$261K Sell
4,124
-4,390
-52% -$258K 0.13% 237
2024
Q2 		$451K Buy
+8,514
New +$558K 0.24% 114
2024
Q1 		– Sell
-10,743
Closed -$200K – 408
2023
Q4 		$200K Buy
+10,743
New +$140K 0.12% 206
2023
Q2 		– Sell
-26,737
Closed -$445K – 468
2023
Q1 		$445K Buy
+26,737
New +$276K 0.21% 138

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Diametric Capital's VKTX Position: Q2 2026 in Review

Diametric Capital sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 63,896 shares — an estimated $2.08M sold.

Diametric Capital first reported a position in VKTX in Q1 2023 and held it in 5 quarters. The position peaked at $2.08M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Diametric Capital reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 63,896 Viking Therapeutics shares in Q2 2026, an estimated $2.08M.
  • Diametric Capital first reported a position in Viking Therapeutics in Q1 2023 and held it in 5 quarters.
  • Diametric Capital's Viking Therapeutics position peaked at $2.08M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.